BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,200+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma.
EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives by promoting innovation. We connect the right people and the right topics across European borders, so that innovation can happen at the intersection of research, education and business.
Founded in 2009, LifeSci Advisors sits at the heart of the LifeSci Partners platform, providing comprehensive investor relations, corporate communications & capital markets advisory to Life Sciences clients. Our experienced teams on the ground in the U.S, Europe and Israel are made up of former healthcare equity sales professionals, investment bankers, portfolio managers, analysts, journalists, scientists and corporate IR & communications professionals – all with 15+ years of Wall Street experience. We leverage our domain expertise to globally secure quality, one-on-one meetings with specialist healthcare investors and HNWI/family offices, for our clients. LifeSci are the global leaders in non-deal-roadshows with 9,800+ investor meetings executed for our clients in 2020 and $15B Aggregate client financings globally over 10 years.
A global investment banking boutique serving companies in the life sciences industry. Since our inception in 2007, we have advised clients on more than $100 billion worth of deals for biotechnology, branded pharmaceutical, generic pharmaceutical, and life sciences companies. Our partners are senior industry bankers and executives, with deep experience, knowledge, and networks. We are a partner of choice for companies seeking discreet, conflict-free, and knowledgeable advice on M&A, pharmaceutical asset sale, capital markets, and licensing transactions. Torreya is differentiated from most other life sciences advisory practices by the breadth of its global presence. Over half the transactions on which we advise are cross-border. Torreya has offices in London, Mumbai, and New York, and affiliate offices on six continents.
The Office for Economic Affairs and Innovation (SPEI) supports companies that are located in the State of Vaud, especially those involved in the sectors of advanced technology and industry. SPEI advises entrepreneurs and puts them in contact with organizations that are appropriate to their specific needs. SPEI can also provide direct financial support.
Oppenheimer and Oppenheimer Asset Management Inc. (OAM) are principle subsidiaries of Oppenheimer Holdings Inc., and provide a full range of wealth management, securities brokerage, capital markets, and investment banking services to high-net worth individuals, families, corporate executives, businesses and institutions. The Firm creates integrated financial strategies tailored to each client’s goals. For over 130 years of operation, Oppenheimer has emphasized customer service, integrity and intellectual objectivity.
AWS is the trusted technology partner to the global healthcare and life sciences industry. For over 14 years, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud platform. Trusted by thousands of healthcare and life sciences customers around the world—including the fastest-growing startups, the largest enterprises, and the leading government agencies. AWS offers secure and compliant solutions to keep protected health information (PHI) private enabling the highly regulated healthcare and life sciences industry to increase the pace of innovation, unlock the potential of data, improve clinical and operational efficiency, and personalize the healthcare journey, improving the healthcare experience and ultimately patient outcomes. aws.amazon.com/health/
The BioInnovation Institute Foundation (BII) is an international non-profit foundation supported by the Novo Nordisk Foundation. BII operates an incubator to accelerate world-class life science innovation that drives the development of new solutions by early-stage life science start-ups for the benefit of people and society.
BII, located in Copenhagen,, Denmark, offers start-ups and early-stage projects within health tech, therapeutics and bio-industrials state-of-the art labs, vibrant office facilities, business development, start-up business incubation, access to high-level mentoring and international networks plus unique funding opportunities of up to 1.3 million euro per start-up and 2.4 million euro per project.
With continued positive development, The Novo Nordisk Foundation can provide up to EUR 470 (3,5 mia. DKK) to BII over 10 years to support early-stage life science projects and start-ups for the benefit of people and society.
Since the inauguration of BII in November 2018, BII has awarded 48 million euros to 85 high-growth start-up companies.
Latham & Watkins LLP is one of the largest law firms in the world with more than 3,000 lawyers located in major financial, business and regulatory centers around the globe. Our award-winning Healthcare & Life Sciences Industry guides clients through their most significant and cutting-edge legal challenges through a combination of in-depth industry knowledge, legal acumen, and strategic business advice. We understand the unique economic, market, regulatory and political climates in which healthcare and life sciences companies operate. www.lw.com
novo holdings a/s
Novo Ventures is a global team of investment professionals employed by Novo affiliates that supports Novo Holdings’ investments in private, public and structured product opportunities in the life sciences industry. Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding and investment company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Foundation’s assets. Novo Holdings is recognized as a world-leading life science investor with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.
PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For the past 28 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.
PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts from innovators to large pharma makes us uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.
PharmaVentures’ services include:
M&A (divestments, mergers, acquisitions, and strategic transactions)
Licensing (in and out licensing)
Strategy (commercialisation, deal strategy, due diligence, market entry)
Valuation and Positioning (licensing, M&A, fundraising, and expert testimonies)
PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in Asia-Pacific.
PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356).
Syneos Health, we are uniquely positioned to bring into sharp focus the issues that matter most to biotech companies and investors through the breadth and depth of our network, and access to the expertise that the wider Syneos Health organization offers.
We are an end-to-end, fully integrated biopharmaceutical solutions company that works differently. At Syneos Health, all the disciplines involved in bringing new therapies to market, from clinical to commercial and consulting, work together to create customer success. Our unique Biopharmaceutical Acceleration Model (BAM) delivers value across the small to mid-size to large customer continuum.
Our clinical, commercial and consulting offerings live under the same roof and constantly share real world knowledge and insights that lead to getting the job done better, smarter and faster.
TVM Capital Life Science’s investment professionals draw upon the experience, international approach and demonstrated success of about 100 exits from our portfolio. These exits include about 100 initial public offerings on the NASDAQ and various European Exchanges and multiple trade sales and mergers.
With more than two decades of experience in picking promising entrepreneurs, concepts and products for development, and building successful entrepreneurial companies, we are acutely aware of what it takes to build a world class technology, product or company, and astute at supporting management teams to bring companies and projects to value inflection points.